| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07466225 HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion |
overall status: "Not Yet Recruiting" → "Active Not Recruiting" |
| 2026-06-10 | NCT07466225 HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion |
date change Primary completion pushed: 2026-06-30 -> 2026-12-30 |
| 2026-06-10 | NCT07466225 HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion |
date change Completion pushed: 2026-08-31 -> 2027-06-30 |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Recruitment opened |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Primary endpoint(s) modified |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Enrollment reduced: 30 -> 27 participants |
| 2026-06-06 | NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… |
Trial terminated |
| 2026-06-06 | NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… |
critical why stopped: null → "\\<75% participation" |
| 2026-06-06 | NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… |
date change Primary completion pushed: 2026-03-31 -> 2026-05-29 |
| 2026-06-06 | NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… |
date change Completion pushed: 2026-03-31 -> 2026-05-29 |
| 2026-06-04 | NCT07359040 Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell… |
overall status: "Active Not Recruiting" → "Recruiting" |
| 2026-06-04 | NCT07007312 Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With… |
Trial sites expanded: 53 -> 71 locations |
| 2026-06-03 | NCT07508982 Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML |
Recruitment opened |
| 2026-06-02 | NCT07434492 Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy |
Recruitment opened |
| 2026-05-30 | NCT07433023 tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy |
Recruitment opened |
| 2026-05-30 | NCT06445907 Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-30 | NCT06445907 Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute… |
Enrollment reduced: 32 -> 17 participants |
| 2026-05-15 | NCT05379166 Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic… |
date change Completion pushed: 2026-04-15 -> 2026-12-15 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07641010 PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma | Phase 1/2 | Not Yet Recruiting |
| 2026-06-09 | NCT07635485 VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML | Not Yet Recruiting | |
| 2026-06-02 | NCT07619898 PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in… | Phase 2 | Not Yet Recruiting |
| 2026-06-01 | NCT07616154 Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | Phase 2 | Not Yet Recruiting |
| 2026-06-01 | NCT07616336 Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes | Phase 2 | Not Yet Recruiting |
| 2026-05-26 | NCT07605949 Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | Phase 2 | Not Yet Recruiting |
| 2026-05-22 | NCT07601607 Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell… | Phase 1/2 | Not Yet Recruiting |
| 2026-05-20 | NCT07598578 An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide… | Early Phase 1 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07044687 | Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in… | Acute Myeloid Leukemia | Recruiting |
| NCT06370000 | Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML)… | Acute Myeloid Leukemia | Recruiting |
| NCT02081755 | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | Carcinoma, Hepatocellular | Enrolling by Invitation |
| NCT07248644 | Immunosuppressant Discontinuation in Elderly Patients With Ulcerative Colitis And… | Ulcerative Colitis (UC) | Not Yet Recruiting |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | Psoriasis | Not Yet Recruiting |
| Phase 3 | |||
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia… | AML, Adult | Recruiting |
| NCT06497985 | A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR… | Colorectal Cancer | Recruiting |
| NCT07493109 | Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially… | Diffuse Large B-Cell Lymphoma (DLBCL) | Recruiting |
| NCT07168161 | BDB-001 Phase III Trial in ANCA-Associated Vasculitis | ANCA Associated Vasculitis (AAV) | Recruiting |
| NCT05586074 | HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML | Leukemia, Acute Myeloid (AML) | Recruiting |
| NCT05907057 | An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult… | Acute Myeloid Leukemia (AML) | Recruiting |
| NCT06465953 | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With… | Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) | Recruiting |
| NCT05183035 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | Recruiting |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With… | Acute Myeloid Leukemia (AML) | Recruiting |
| NCT06852222 | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With… | Leukemia, Myeloid, Acute | Recruiting |
| NCT07234162 | A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL… | Peripheral T-cell Lymphoma | Recruiting |
| NCT07407660 | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in… | Acute Myeloid Leukemia | Not Yet Recruiting |
| NCT07478991 | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients… | Acute Myeloid Leukemia, Adult | Not Yet Recruiting |
| NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and… | Acute Myeloid Leukemia (AML) | Not Yet Recruiting |
| NCT07469046 | VAH vs VA in Newly Diagnosed Elderly AML | Acute Myeloid Leukemia (AML) | Not Yet Recruiting |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | AML | Not Yet Recruiting |
| NCT07541755 | PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL | Acute T Lymphoblastic Leukemia (T-ALL) | Active, Not Recruiting |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC | Rectal Adenocarcinoma | Not Yet Recruiting |
| NCT04401748 | Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change… | Myelodysplastic Syndrome (MDS) | Active, Not Recruiting |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment… | Acute Myeloid Leukemia (AML) | Active, Not Recruiting |